Novo Nordisk A/S – share repurchase programme
Novo Nordisk A/S Bagsværd, Denmark, 20 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase…
Novo Nordisk releases 2026 sales and operating profit outlook
Novo Nordisk A/S Bagsværd, Denmark, 3 February 2026 – Novo Nordisk today announced sales and operating profit growth at…
Novo Nordisk’s sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025
Novo Nordisk A/S Bagsværd, Denmark 3 February 2026 – Financial report for the period 1 January 2025 to…
Novo Nordisk A/S – share repurchase programme
Novo Nordisk A/S Bagsværd, Denmark, 27 April 2026 – On 4 February 2026, Novo Nordisk initiated a share…
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
Novo Nordisk A/S PIONEER TEENS is the first clinical trial of an oral GLP-1 RA therapy in children…
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
Novo Nordisk A/S PIONEER TEENS is the first clinical trial of an oral GLP-1 RA therapy in children…
Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease
Novo Nordisk A/S Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive…
Novo Nordisk A/S – share repurchase programme
Novo Nordisk A/S Bagsværd, Denmark, 20 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase…
Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease
Novo Nordisk A/S Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive…
Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered
Novo Nordisk A/S Strategic partnership enables upskilling of Novo Nordisk’s workforce and places the company at the forefront…
Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered
Novo Nordisk A/S Strategic partnership enables upskilling of Novo Nordisk’s workforce and places the company at the forefront…
Novo Nordisk A/S – share repurchase programme
Novo Nordisk A/S Bagsværd, Denmark, 13 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase…